Literature DB >> 12566786

Influence of the platelet-activating factor receptor antagonist BB-882 on intra-abdominal adhesion formation in rats.

S Otcu1, H Ozturk, M Aldemir, N Kilinc, A I Dokucu.   

Abstract

Postoperative intra-abdominal adhesion formation is a major clinical problem. We aimed to examine the preventive effect of treatment with the platelet-activating factor (PAF) antagonist (lexipafant, BB-882) on experimentally induced intra-abdominal adhesion formation in rats. Twenty male Sprague-Dawley rats weighing 250 and 290 g were studied. Generation of adhesions in rats by brushing a 1-cm(2) area of the cecum and the peritoneum on the right side of the abdominal wall was followed by intra-abdominal administration of saline and 5 mg/kg in a volume of 0.2 ml PAF receptor antagonist BB-882. After 45 days, formation of adhesions was graded and histological evaluation was processed. The severity of adhesions was significantly less in the BB-882 group than in the control group (p < 0.001, p < 0.05). The average adhesion scores in the control and BB-882 groups were 3.2 +/- 0.6 and 0.6 +/- 0.6, respectively, and the difference between both groups was found to be significant (p < 0.0001). The number of polymorphonuclear leukocytes and fibrotic areas was significantly decreased in the BB-882 group when compared to the control group (p < 0.001, p < 0.002). In conclusion, this study confirms the efficacy of BB-882 in the prevention of postoperative intra-abdominal adhesions in a rat model. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566786     DOI: 10.1159/000067034

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  2 in total

Review 1.  [Late complications of open abdomen].

Authors:  F Eder; J Tautenhahn; H Lippert
Journal:  Chirurg       Date:  2006-07       Impact factor: 0.955

2.  Visceral adhesions to hernia prostheses.

Authors:  W B Gaertner; M E Bonsack; J P Delaney
Journal:  Hernia       Date:  2010-04-18       Impact factor: 4.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.